About Samjin Pharm
Samjin Pharm is a company based in Seoul (South Korea) founded in 1972. The company has 809 employees as of December 31, 2024.
- Headquarter Seoul, South Korea
- Employees 809 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Samjin Pharmaceutical Co., Ltd.
-
Annual Revenue
$213.92 M (USD)0.25as on Dec 31, 2025
-
Net Profit
$16.44 M (USD)-39.47as on Dec 31, 2025
-
EBITDA
$33.25 M (USD)35.8as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
809
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Samjin Pharm
Samjin Pharm is a publicly listed company on the KRX with ticker symbol 005500 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Samjin Pharm
Detailed funding history for Samjin Pharm
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Samjin Pharm
Investment portfolio details for Samjin Pharm
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Samjin Pharm
Detailed financials for Samjin Pharm
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Samjin Pharm Comparisons
Peer comparison for Samjin Pharm
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Samjin Pharm
Detailed competitors of Samjin Pharm
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Samjin Pharm
Complete news archive for Samjin Pharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Samjin Pharm
Samjin Pharm was founded in 1972.
Samjin Pharm is headquartered in Seoul, South Korea.
Sung-Woo Lee is the current CEO of Samjin Pharm.
As of Dec 31, 2024, the latest employee count at Samjin Pharm is 809.
Annual revenue of Samjin Pharm is $213.92M as on Dec 31, 2025.
Samjin Pharm was founded in 1972 and is based in Seoul, South Korea. Therapies targeting HIV, cancer, and neurodegenerative diseases are developed by the company. Its lead candidate, SA001, is currently in phase II trials for dry eye syndrome treatment. Clinical development services are also provided, encompassing drug synthesis, toxicological studies, formulation laboratory work, and process development for new synthesis methods.
Yes, Samjin Pharm is publicly traded on KRX under the ticker symbol 005500.
The ticker symbol of Samjin Pharm is 005500 on KRX.